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ABSTRACT
Sirpa Heina¨vaara: Modelling survival of patients with multiple can-
cers
With increasing number of subsequent primary cancers there is a growing
concern to know how cancer patients survive with their subsequent cancer
compared to those with their respective first cancer. Results of earlier studies
have been conflicting and have not lead to firm conclusions. One reason for
conflicting results might be a lack appropriate methodology as survival from
subsequent cancer has usually not been adjusted for an extra hazard due to
an underlying first cancer.
This study presents four alternative models for estimating survival of patients
with multiple cancers. Models are extensions and modifications to those pro-
posed earlier for estimating relative and cause-specific survival of patients with
a single cancer. The assessment of survival from subsequent cancer raised a
need for introducing new concepts, especially when survival of patients with
their multiple cancers of the same site is concerned. Survival estimates from
cancer are compared between the models, and between a first and subsequent
tumour of the same site. The importance of adjusting survival from subse-
quent cancer to that from a underlying first cancer is also highlighted.
The results show that survival from cancer as a first and subsequent tumour
can be reliably assessed with the newly introduced models based either on
the relative and cause-specific survival. The results also show that survival
from cancer as a first and subsequent tumour may be dependent on the site
of cancer and whether patients’ cancers are of the same site or not. Neverthe-
less, survival from a subsequent cancer is not usually different from that from
a respective first cancer. However, even with large population-based data, a
lack of power often prevents the detection of modest differences in survival.
Keywords: multiple cancers, subsequent cancer, relative survival, cause-specific
survival
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ABBREVIATIONS
The following abbreviations are used throughout this thesis:
c site of cancer of primary interest
c1 a first primary cancer of site c
c0 a first primary cancer of site non-c
c2 a subsequent primary cancer of site c
diagnosed after a first primary cancer
cv, v=1,2 cancers c1 and c2 of site c, or
cv, v=0,1,2 cancers c1 and c2 of site c and cancer c0 of site non-c
cf, f=0,1 a first cancer c0 or c1
λv, v=0,1,2 a hazard of dying from cancer cv
λe a hazard of dying in a general population group
λT a total mortality hazard of dying from any cause
TO SUMMARIZE:
• If patients have their multiple cancers at different sites, cancers are called
c0 and c2.
• If patients have their multiple cancers of the same site, cancers are called c1
and c2.
ERRATUM
The sentence on the right-hand column on page 147 of article III, 9th line from
the bottom, starting with
Their model was based on an assumption that the follow-up times of those
non-cured follow a Weibull distribution, ... should be
Their model was based on an assumption that the survival of those non-cured
follow a Weibull distribution, ....
In addition, equation for Sv(tv, zv) on page 148 of acticle III should be
Sv(t, zv) = [Pv + (1− Pv) exp(−(αvt)γv)]exp(β>v zv).
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2 INTRODUCTION
At an individual level, a diagnosis of cancer can be regarded as a human
tragedy, and at the level of society, cancers are the major diseases causing a
notable amount of health administrative costs. Prognosis and possible cure
from cancer are thus important measures. Both of them can be assessed by
analysing the survival of cancer patients.
Survival of cancer patients is known to be dependent on prognostic factors
such as age at diagnosis, gender of the patient and site of the cancer. Since
the site of the cancer often has a significant effect on survival, one may be
especially interested in survival from cancer at a specific site while simulta-
neously accounting for the effects of prognostic factors. Survival from cancer
can be assessed by estimating relative or cause-specific survival.
With improved survival from cancer and ageing of populations, the numbers
of subsequent primary cancers are increasing. In Finland, the number of reg-
istered subsequent primary cancers increased from 7,400 in calendar period
1970-79 to almost 32,000 in 1990-99. The increase is evident although that
7,400 can be an underestimation since the information on the first primary
cancers diagnosed before 1953 is not available. As a consequence, estimates of
survival from subsequent cancer are of growing interest, and there is an interest
in comparing survival from a certain cancer as a first and subsequent tumour.
For such comparisons, however, survival from subsequent cancer should be
properly estimated and adjusted for available prognostic factors.
New concepts are needed in assessing survival from subsequent cancer. The
need is evident especially when survival of patients with two primary cancers
of the same site are studied. One should, for example, be able to distinguish
between survival from breast cancer as a first tumour and breast cancer as a
subsequent tumour. Moreover, there should be a concept for assessing survival
from a first or subsequent cancer as well as survival from both cancers together.
This study aims at developing concepts and models for assessing survival from
cancer as a first and subsequent tumour while simultaneously controlling for
the effects of other prognostic factors. Special attention is paid to survival
of patients with two cancers of the same site. Survival from cancer as a first
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and subsequent tumour is assessed by semi-parametric models for relative and
cause-specific survival. Survival from cancer as a first and subsequent tumour
is also assessed simultaneously with proportions cured from cancer using a
parametric mixture model for relative survival. Survival estimates from can-
cer are compared between the models, and between a first and subsequent
tumour of the same site. A detailed list of the aims is presented in section 4.
The proportion of patients with more than two primary cancers among pa-
tients with multiple primary cancers is rather small even if it is increasing with
calendar time: In 1970-79, 92 % of subsequent primary cancers were secondary
cancers whereas in 1990-99, 84 % were secondary. This study concentrates on
assessing survival from one subsequent primary cancer of interest. Patients
with two primary cancers are from now on called patients with multiple (pri-
mary) cancers or multiple-cancer patients, and patients with one (primary)
cancer are referred to as single-cancer patients.
3 LITERATURE REVIEW
3.1 Survival of multiple-cancer patients
Studies of the survival of multiple-cancer patients have been shown conflict-
ing results: Patients diagnosed with a subsequent cancer may survive better
than [1, 2, 3, 4], worse than [5] or similarly to [6, 7, 8] patients a first cancer
in the same site. Results may be dependent on the site of cancer but even
the studies of survival of patients with multiple breast cancers have been non-
conclusive [2, 5, 7, 8]. The number of patients with subsequent cancer may
also have been too small to draw definitive conclusions [9].
One possible reason for these non-conclusive results may be due methodolog-
ical drawbacks, as discussed earlier by Sankila and Hakulinen [4, 10]. These
methodological problems include the lack of adjustment for prognostic factors
such as age and stage of cancer [6, 11], ignoring the time interval between the
diagnoses of a first and subsequent cancer [1, 11], estimating overall survival
instead of survival from cancer [8, 11, 12], and most of all, not appropriately
accounting for the mortality associated with the first primary cancer.
3
To avoid the methodological difficulties in the previously published studies,
Sankila and Hakulinen [4, 10] proposed a new method for estimating relative
survival of multiple-cancer patients. The method is an extension to the anal-
ysis of relative survival of single-cancer patients based on life-table estimates
and grouped data. The method is presented briefly in [4] and with details
in [10]. Sankila and Hakulinen studied survival from a subsequent colorectal
cancer, diagnosed after a first breast cancer, and compared it with that from
a first colorectal cancer. Survival from subsequent colorectal cancer was ad-
justed for the prognostic factors and for the fixed excess hazard of the first
breast cancer. The method by Sankila and Hakulinen and the new models are
compared in section 8.1.
3.2 Survival of single-cancer patients
The new models presented in this thesis are extensions and modifications to
existing models for analysing survival from cancer of single-cancer patients.
Survival from cancer has usually been assessed with the analysis of relative or
cause-specific survival [13, 14] with so-called semi-parametric models. In these
semi-parametric models, prognostic factors are incorporated with some para-
metric form but nothing, or almost nothing, has been assumed on the survival
distribution. Survival from cancer has also been estimated with proportion
cured from cancer using parametric mixture [15] and non-mixture [16] models.
In the analysis of relative survival of patients with a single cancer c1, the total
mortality hazard λT is assumed to consist of an expected mortality hazard
λe, usually estimated from a respesentative general population group, and an
excess hazard λ1 attributable to cancer c1. In the analysis of cause-specific
survival, the deaths from cancer c1 contribute to the cause-specific hazard λ1.
The relative and cause-specific survival at follow-up time t1, S1(t1), is a func-
tion of the cumulative hazard Λ1(t1) until t1, namely S1(t1) = exp(−Λ1(t1)).
The analysis of relative survival is thus possible if patients are known to have
died or been censored but in the analysis of cause-specific survival, a cause of
death must be defined to be either cancer c1 or non-c1.
The analysis of relative and cause-specific survival are traditionally based on
grouped data. Using the method by Este`ve et al. [14], survival from cancer
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can also be estimated using individual patient data. The original method was
applicable only when the effect of prognostic factors was proportional to a
baseline (proportional hazards) but it has later been modified to include non-
proportional hazards [17].
In parametric mixture and non-mixture models, survival is estimated simulta-
neously with a proportion cured from cancer. In parametric mixture models,
a patient is assumed, at the diagnosis of his or her cancer, to belong to an
unknown proportion of patients cured from cancer P or to that of patients
who are bound to die from cancer 1 − P . Those belonging to the proportion
cured are bound to die only due to the other causes of death similarly [15], or
proportionally similarly [18], to those in the corresponding general population
group, and those belonging to the proportion non-cured are assumed to sur-
vive from cancer according to a pre-defined parametric survival distribution
Sc. In a parametric mixture model, survival from cancer of all patients S is
thus estimated with S = P + (1 − P )Sc. The proportion cured is considered
to be a function of prognostic factors [19], and survival Sc is often assumed to
follow a Weibull [15, 16, 19] or a log-normal [20, 21] distribution. The para-
metric non-mixture models are based on an assumption that the proportion
cured P is an asymptotic limit of survival from cancer S [16, 22, 23].
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4 AIMS OF THE STUDY
The specific aims of the study are as follows:
1. To develop concepts for assessing survival of patients with multiple cancers
[I-IV].
2. To develop flexible and easily applicable models for estimating survival
from cancer as a first and subsequent tumour [I-IV] based on the analysis of
the relative and the cause-specific survival.
3. To develop models for estimating cause-specific survival of multiple-cancer
patients based on available information on the cause of death, either as an
official cause of death or as a cancer-specific (tumour-specific) cause of death
[II].
4. To develop a model for assessing proportions cured from cancer as a first
and subsequent tumour [III].
5. To compare a new relative survival model with the respective method by
Sankila and Hakulinen, and to apply the new model with large empirical data
on patients with multiple cancers [IV].
6. To include the effects of prognostic factors into survival in all the models
[I-IV].
7. To compare survival from cancer between a first and subsequent primary
tumour [I-IV].
8. To study possible associations between a first and subsequent tumour of
multiple-cancer patients using time interval between the diagnoses as a possi-
ble prognostic factor for survival from a subsequent cancer [I-IV].
In all of these aims, the precision of all the parameters should be estimable
and the individual variability should be taken into account as well as possible.
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5 MATERIALS
Population-based data on cancer patients have been available at the Danish
Cancer Registry since 1943 and at the Finnish and Norwegian cancer registries
approximately a decade later. In all of these countries, the notification of new
cancer cases in compulsory, in Denmark since 1987 [24]. Reporting is based
on multiple sources including physicians, hospitals, institutions with hospital
beds, pathological and cytological laboratories and death certificates. Cover-
age of almost 100% is achieved in all of these countries [25].
Since each resident of the Nordic countries has a unique personal identifica-
tion number, linking of individual records is simple and reliable. The reliable
identification and the follow-up of patients with multiple primary cancers was
essential for this study. The Nordic cancer registries link their records of indi-
vidual cancer patients also with the official cause of death [25]. At the Finnish
Cancer Registry, the relationship between the cancer and the official cause of
death is additionally recorded with a special code, a cancer- or tumour-specific
cause of death, for each primary cancer.
Publications I-III are based on Finnish data supplied by the Finnish Cancer
Registry and publication IV on Danish, Finnish and Norwegian data supplied
by the respective cancer registries. For publications
• I-II, the data consisted of Finnish female patients diagnosed with one or two
primary breast cancers;
• III, the data consisted of Finnish male patients diagnosed with first primary
localized colorectal cancer possibly followed by a second primary lung cancer
and, for survival comparisons, of Finnish male patients diagnosed with a first
primary lung cancer; and
• IV, the data consisted of Danish, Finnish and Norwegian male patients
diagnosed with subsequent primary prostate cancer after the first primary
colorectal cancer, and for comparisons, of respective male patients with a first
primary prostate cancer.
Since the Nordic cancer registries collaborate on standardization of registra-
tion and classification [25], the Danish, Finnish and Norwegian data were easy
to standardize with the major exception being the stage of cancer: The coding
practice for the stage of cancer varies from one Nordic country to another.
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For the estimation of relative survival (I,III-IV), the expected general popu-
lation mortality hazards λe were needed. The λe(s, a, p, C) were tabulated by
gender s, one-year age group a (a=0,1,...,99), 5-year calendar time period p
and country C (Denmark, Finland, Norway). For patients aged more than 99
years at the end of the follow-up, the λe(s, 99, p, C) were used. In Denmark,
the λe(s, 90+, p,Dk) were received as pooled, 90+ referring to those at least
90 years old. The one-year age-specific λe(s,m, p,Dk),m=90,...,99, were cal-
culated by assuming that the ratio between the Danish λe(s, 85 − 89, p,Dk),
pooled over ages 85-89, and the Norwegian λe(s, 85 − 89, p,N) was the same
also for age m given s and p.
6 METHODS
6.1 General background
In the analysis of relative survival of patients with multiple cancers c1 and c2,
an excess hazard λ1,2 was assumed to be due to both cancers c1 and c2. In
the corresponding analysis of cause-specific survival, deaths from either of the
cancers c1 or c2 contribute to the cause-specific hazard λ1,2.
According to the theory of competing risks one may decompose for a patient
group of single- and multiple-cancer patients that
λ1,2(t1, t2) = λ1(t1) + c2λ2(t2),(1)
where c2 is an indicator whether a patient is a single-cancer (c2 = 0) or a
multiple-cancer (c2 = 1) patient, and λ2(t2) is a hazard related to a subse-
quent cancer c2 at time t2 since the diagnosis of c2.
Although t1 and t2 represent times since diagnoses of c1 and c2, respectively,
λ1,2(t1, t2) has only one time dimension: If x1 and x2 are the ages at diagnoses
of cancers c1 and c2, respectively, then t2 = t1−(x2−x1) with 0 ≤ t2 ≤ t1 <∞.
The additivity of the hazards shown in equation (1) does not imply that the
hazards are independent [26]. For the estimation of proportions cured from
cancers c1 and c2 with a parametric mixture model (III), an assumption of
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independence is required: given the values of prognostic factors, survival from
cancer c2 should be independent of that from cancer c1. This assumption must
be and has been motivated further with the presentation of the data used in III.
The λ1 in equation (1) is assumed to be the same for single- and multiple-
cancer patients with their first cancer c1. Since it is not known in advance
who is to become a multiple-cancer patient and who is not, the inclusion of
all single-cancer patients is required for the estimation of λ1. Moreover, when
the estimation of the λ1 is based on all possible data, its estimate will be pre-
cise. It could of course be studied whether λ1 for single-cancer patients equals
that for multiple-cancer patients. However, the number of multiple-cancer pa-
tients is small for the simultaneous estimation of parameters related to two
hazards, and thus the statistical power to study this question is rather limited.
It is of primary interest to study whether the hazard λ2 of a subsequent cancer
c2 of site c is the same, or proportional to the corresponding hazard λ1 of a first
cancer c1 of site c. If multiple-cancer patients have their cancers at the same
primary site, only the hazards λ1 and λ2 are estimated. Usually, however,
cancers of multiple-cancer patients are not at the same site. In this case the
underlying hazard λ0 of cancer of site non-c is also estimated. Let λv denote
for all the hazards, v=1,2 for patients with multiple cancers of the same site,
and v=0,1,2 otherwise, and let λf be the hazard of the first cancer, f=0,1. The
hypothesis of the proportionality of hazards between a first and subsequent
tumour at site c can also be expressed formally with
H0 : λ2 = pλ1 vs H1 : λ2 6= pλ1,(2)
where p is a constant to be estimated.
To use all the possible information, especially on patients with a subsequent
cancer c2, the estimation of λv is based on individual patient data. The semi-
parametric approach presented by Este`ve et al. [14] for estimating survival
from cancer of single-cancer patients was chosen as a basis for the further
development (I,II,IV). The survival and proportions cured from cancer as a
first and subsequent tumour (III) were estimated using an extension to a para-
metric mixture model which was introduced in personal discussion with Dr.
Arduino Verdecchia, Instituto Superiore di Sanita’, Rome, Italy, and which is
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a modification of a model proposed earlier by De Angelis et al. [15]
6.2 Adjustment for prognostic factors
The λv are known to vary with follow-up time tv and with prognostic factors
zv, and should therefore be more accurately denoted as λv(tv, zv).
In applications I, II and IV, λv is assumed to be piecewise constant with follow-
up time tv for patients with zv=0. The effect of prognostic factors zv on λv is
assumed to be proportional with respect to follow-up time tv.
In the semi-parametric method following Este`ve et al. [14], a hazard can be
written as
λv(t, zv) = exp(β>v zv)
mv∑
k=1
τvkIvk(t),(3)
where βv is a vector of parameter estimates for prognostic factors, τvk >0 is a
baseline hazard during the discrete time interval k for patients with zv = 0,
mv is the number of discrete time intervals after the diagnosis of cancer cv,
and Ivk(t) is an indicator function of the kth interval.
In application III based on a parametric mixture model, survival of those
non-cured S1−Pv , v=0,1,2, is assumed to follow a Weibull distribution, and
prognostic factors zv are assumed to affect both the proportion cured Pv from
cancer cv and survival S1−Pv . The adjustment of prognostic factors can be
understood through survival from cancer Sv which can be estimated with
Sv(t, zv) = [Pv + (1− Pv) exp(−(αvt)γv)]exp(β>v zv), αv, γv > 0,(4)
where αv and γv are shape and scale parameters, respectively, and βv is a
vector of prognostic factors.
The hazard λv can then be calculated as
λv =
−d log(Sv(t, zv))
dt
(5)
= exp(β>v zv)
(1− Pv) exp(−(αvtv)γv)(αvtv)(γv−1)αvγv
Pv + (1− Pv) exp(−(αvt)γv) .
10
The time interval between the diagnoses of the subsequent cancer c2 and the
underlying first cancer cf , and tumour rank indicator (first or subsequent)
were considered as potential prognostic factors for the λ2. The time interval
between the diagnoses was classified into categories based on the behaviour of
the underlying hazard λf , f = 0, 1 and was used as a categorical variable in
modelling. The effect of the tumour rank indicator was tested only when the
effect of follow-up time tv on the λv was proportional between cancers c2 and
c1.
0.1 Models for estimating survival from cancer as a first and
subsequent tumour
Usually the hazard λ1,2 > λ2 unless the time interval between the diagnoses
of cancers c1 and c2 is so long that λ1 ≈ 0 and thus λ1,2 ≈ λ2. In practice,
survival from cancer cv is of primary interest when the λv > 0, that is, when
there is additional mortality due to cancer cv. The mathematical restrictions,
λv ≥ 0 needed later in model (6) and λv > 0 needed in (7-9), are therefore not
limiting in practice.
Let us consider survival of patients with multiple cancers at different sites.
Let the number of patients diagnosed with a first cancer c1 at site c be N1
and the number with a first cancer c0 at site non-c be N0. Each patient i
has prognostic factors zvi, follow-up times tvi up to death or censoring, an
individual hazard λvi(tvi, zvi), an individual cumulative hazard Λvi(tvi, zvi)
and a fixed expected mortality hazard λei(tfi + xfi, z∗fi); xfi is the age at
diagnosis of cancer cf, f=0,1, and z∗fi may be regarded as a sub vector of zfi.
The arguments for follow-up time tvi and covariates zvi as well as the possible
constants have been omitted from the log-likelihoods.
0.1.1 Semi-parametric model for relative survival
For comparisons of survival from cancer as a first and subsequent tumour, c1
and c2, individual contributions to the log-likelihood Lr can be written as
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Lr =
N0∑
i=1
[−Λ0i − c2iΛ2i + δi log(λei + λ0i + c2iλ2i)] +(6)
N1∑
j=1
[−Λ1j + δj log(λej + λ1j)],
where δi and δj are indicators whether patients i and j, respectively, died
(δi = δj = 1) or were censored (δi = δj = 0) in the study period; and c2i is an
indicator whether patient i was diagnosed with a subsequent cancer c2 (c2i=1)
or not (c2i=0) in the study period.
6.3.2 Semi-parametric models for cancer-specific survival
In the analysis of cause-specific survival of patients with multiple cancers,
analogously to that of single-cancer patients, a death from cancer should be
attributed to a first tumour cf or a subsequent tumour c2. Given that the
official cause of death exists, such a distinction is usually possible, i.e, cancer-
specific (tumour-specific) causes of death can be derived. For patients with
multiple cancers of the same site, however, this may not be possible. The anal-
ysis of cancer-specific survival of patients with multiple cancers should thus
be possible in two alternative ways depending on whether the cancer-specific
causes of death are known or not.
The concept of cancer-specific survival is liable to misunderstanding especially
when data consist of patients with multiple cancers of the same primary site.
The concepts of cancer-specific (tumour-specific) and c1- and c2-specific sur-
vival were therefore introduced to refer to survival from cancers c1 and c2,
respectively.
Cancer-specific causes of death known (Cancer-specific survival model 1)
If a death from cancer can be distinguished between a first and subsequent
tumour, individual contributions to the log-likelihood Lcs1 can be written as
Lcs1 =
N0∑
i=1
[−Λ0i + δ0i log(λ0i) + c2i(−Λ2i + δ2i log(λ2i))] +(7)
N1∑
j=1
[−Λ1j + δ1j log(λ1j)]
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where δvp indicates whether patient p, p = i, j died from his or her cancer cv
in the study period (δvp=1) or not (δvp=0).
Cancer-specific causes of death not known (Cancer-specific survival model 2)
If a death from cancer cannot be distinguished between a first and subsequent
tumour, or one is not willing to do so, the individual contributions to the
log-likelihood Lcs2 of the model can be written as
Lcs2 =
N0∑
i=1
[−Λ0i − c2iΛ2i + δci log(λ0i + c2iλ2i)] +(8)
N1∑
j=1
[−Λ1j + δ1j log(λ1j)],
where δci indicates whether patient i died (δci=1) either from his or her can-
cers, c0 or c2, in the study period or was censored (δci=0); and δ1j indicates
whether patient j died (δ1j=1) from his or her cancer c1 in the study period
or was censored (δ1j=0).
6.3.3 Parametric mixture model for relative survival
Survival from cancer Sv(tvi, zi), v=0,1,2, can be defined for patient i using
equation (4). The individual contributions to the log-likelihood Lp of the
model can then be written as
Lp =
N0∑
i=1
[log(S0i) + c2i log(S2i) + δi log(λei + λ0i + c2iλ2i)] +(9)
N1∑
j=1
[log(S1j) + δj log(λej + λ1j)].
For the corresponding survival analysis of patients with multiple cancers of
the same site, an underlying cancer c0 should be renamed as cancer c1 and
individuals j should be excluded.
6.4 Implementation of the models
The −log-likelihoods Lcs1 and Lcs2 of the models (7) and (8) were minimized
using the ms() -function in Splus5 [27] under Linux, and Lr and Lp of the mod-
els (6) and (9) with the CML (Constrained Maximum Likelihood) function in
Gauss 4.0 [28]. For models (7) and (8) the approximative standard errors of
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the parameters were calculated from the inverse of the observed information
matrices. The first and second derivatives of Lcs1 and Lcs2 are presented in
the Appendix.
In some situations, especially when data consist of patients with multiple can-
cers at different sites, the simultaneous estimation of all parameters related to
cancers cv, v=0,1,2 can be somewhat unnecessary and overly time-consuming.
Often the parameter estimates related to the underlying first cancer c0 are
not of primary interest and do not change whether they are estimated simul-
taneously with the other parameters or not. One may therefore first estimate
the parameters related to the first underlying cancer c0, calculate model-based
hazards λˆ0i and Λˆ0i for each patient i and regard these hazards fixed when
parameters related to cancers c1 and c2 are estimated simultaneously. For the
estimation of the parameters related to cancer c0 alone, the log-likelihoods
(6)-(9) should be modified by excluding the contributions due to cancer c1, by
censoring the follow-up times t0i at ages x2i − x0i for those with c2i = 1 and
by setting c2i = 0 for all patients i. This approach was used in application
IV with the log-likelihood (6). The possible drawbacks of this approach are
discussed in section 8.1.1.
7 RESULTS
The effect of stage on the hazard λf was found to be non-proportional with re-
spect to follow-up time tf , f=0,1 in all studies. To allow comparisons between
the λ1 and λ2 of interest, all hazards λv were assumed to be non-proportional
between the stages of cancer cv. In I-III, the non-proportionality was han-
dled by stratifying the λv by stage. In IV, the hazards λf , f=0,1 were non-
proportional also between the countries and were modelled by country with
time-dependent covariates for the first years of the follow-up after which they
were assumed to be proportional.
Survival from cancer v, v=0,1,2 is illustrated with model-based relative or
cancer-specific survival Sˆv by stage. Survival from cancers cf, f=0,1 and c2
together is illustrated with model-based overall relative or cancer-specific sur-
vival Sˆf,2, f=0,1, by stage.
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The data on Finnish female patients with one or two primary breast cancers
were analysed with the cancer-specific survival models 1 (7) and 2 (8) and
the relative survival model (6). The comparisons between the cancer-specific
survival models 1 and 2 showed that death from breast cancer, either from the
first or subsequent tumour, provided sufficient information to enable estima-
tion of the c1- and c2-specific (cancer-specific) survival (II). This conclusion
was based on the comparison between the values of the log-likelihoods and the
Akaike Information Criterion.
Cancer-specific survival models 1 and 2, and the relative survival model gave
similar estimates for survival from breast cancer as a first and subsequent
tumour with few exceptions. Model-based survival from the subsequent breast
cancer based on cancer-specific survival model 1 tended to be lower than those
based on the other two models, and for the oldest patients (70+) with the first
breast cancer, model-based relative survival was higher than the corresponding
cancer-specific survival.
Figure 1 Model-based survival from breast cancer as a first and subsequent tumour
by stage in age groups 50-59 and 70+ in calendar year 1992. Survival from the first
breast cancer is estimated with relative and cancer-specific survival model 1 and that
from the subsequent breast cancer with relative and cancer-specific survival models 1
and 2.
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Figure 1 illustrates model-based estimates of survival from breast cancer as the
first and subsequent tumour by stage in age group 50-59 and 70+ for calendar
year 1992. For the first breast cancer, model-based cancer-specific survival is
practically identical between models 1 and 2, and thus only estimates based
on cancer-specific survival model 1 are shown.
All three models (6-8) lead to the conclusion that survival from subsequent
breast cancer was different from that from the first breast cancer (I,II). The
quantification of the difference was, however, difficult since the effect of follow-
up time on the stage-specific hazard λv was non-proportional between the first
and subsequent breast cancer, v=1,2, especially for patients with non-localized
cancer.
In the parametric mixture model, model-based overall relative survival (and
proportions cured) of multiple-cancer patients are products of model-based
relative survival of (and proportions cured from) the first and subsequent can-
cer. The left-hand side of Figure 2 illustrates survival from localized cancer in
the form of first lung cancer c1, as a first colorectal cancer c0, and as a first
colorectal cancer c0 and a second lung cancer c2 together, subsequent being
diagnosed 2 or 5 years apart. The left-hand side also shows how the hazard of
dying from the underlying cancer c0 diminishes and disappears with follow-
up time whereafter the long-term model-based relative survival of single- and
multiple-cancer patients become practically identical. The right-hand side of
Figure 2 illustrates the need for the adjustment: survival from subsequent can-
cer c2 should not be addressed unless it has not been adjusted for the hazard of
the underlying first cancer c0. Model-based relative survival of multiple-cancer
patients (c0&c2, 2 and 5 years apart) can be considered unadjusted or overall
model-based relative survival for subsequent cancer c2 whereas survival from
cancer (c2) refers to adjusted survival. Survival from lung cancer as a first and
subsequent tumour was not found to be different but there was suggestive evi-
dence that survival from subsequent cancer could be higher than that from the
corresponding first cancer (III). The right-hand column of Figure 2 shows that
the unadjusted survival from subsequent cancer is lower than the adjusted one.
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Figure 2 Model-based survival from the first localized colorectal cancer (c0), the first
localized lung cancer (c1), the subsequent localized lung cancer (c2), and the first
localized colorectal cancer c0 and the subsequent localized lung cancer c2 together,
subsequent being diagnosed 2 (c0&c2, 2 years apart) or 5 years (c0&c2, 5 years apart)
after the first colorectal cancer. In the plots on the left-hand side, follow-up time
is given since the diagnosis of the first cancer (c0 or c1) and in the plots on the
right-hand side, since the diagnosis of lung cancer (c1 or c2). Model-based survival
has been calculated with the parametric mixture model for Finnish male patients
diagnosed with their cancer (c0, c1 and c2) between ages 60-69 during the calendar
period 1983-96.
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The need for adjustment for the underlying first cancer c2 is equally evident
when semi-parametric models are used. Figure 3 shows model-based relative
survival for prostate cancer in Norway as a first cancer c1, as a subsequent
cancer c2 after colorectal cancer c0 (c2, adjusted), and as first colorectal c0 and
subsequent prostate cancer c2 together (c0&c2, unadjusted) with diagnoses 3
years apart.
Figure 3 Model-based survival from the first localized prostate cancer (c1), from the
subsequent localized prostate cancer (c2), and from the first localized colorectal can-
cer c0 and the subsequent localized prostate cancer c2 (c0&c2) together, subsequent
being diagnosed 3 years after the first colorectal cancer. Model-based survival is cal-
culated with the relative survival model using Norwegian data on patients diagnosed
with their prostate cancer between ages 70-72 in calendar period 1985-97.
The effect of time interval between the diagnoses of cancers cf, f=0,1 and c2
on the λ2 was tested in all studies. It was found to be clinically small and
statistically non-significant at the 5% level in all studies and was therefore
usually excluded from the final analyses (I-III). In other words, the additional
risk for death from subsequent cancer was not affected by the time interval
since the underlying first cancer. When the effect of follow-up time tv on λv
was proportional between the cancers c1 and c2 (III-IV), the effect of tumour
rank on the λ2 was tested. It was also clinically small and statistically non-
significant at the 5% level in both studies.
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8 DISCUSSION
Stage-specific survival from breast cancer was different between the first and
subsequent cancer (I,II). In the studies of patients with multiple cancers at
different sites (III,IV), stage-specific survival from cancer as a first and subse-
quent tumour was not found to be different. One reason for the lack of a dif-
ference in survival in these latter studies could be the lack of statistical power.
The data on female patients with multiple breast cancers were the largest
Finnish data with respect to the number of subsequent primary cancers. For
breast cancer (I-II), survival comparisons were also based on within-patient
variation whereas the other comparisons were based on between-patient vari-
ation (III,IV). One of the aims of the Nordic study (IV) was the pooling of
Danish, Finnish and Norwegian data to enable derivation of clinically mean-
ingful results with adequate statistical precision. However, the hazards of the
first prostate and colorectal cancer were non-proportional between the stages
of cancer and between the countries, so direct pooling could not be done.
8.1 Comparison between the survival models
8.1.1 Sankila and Hakulinen’s method vs. new survival models
All the log-likelihoods of the new models (6)-(9) were based on individual pa-
tient data. With such data, proper testing of the equality and proportionality
of the hazards was possible and all subsequent primary cancers could be in-
cluded in the analysis. In the method by Sankila and Hakulinen [4, 10] based
on grouped data, survival from an underlying first cancer is considered fixed
and thus proper testing of alternative hypotheses is not possible for reasons
discussed later in this chapter. In practice the effect of fixing depends on
whether multiple-cancer patients have their cancers at the same site or not. If
multiple-cancer patients’ cancers are at different sites, survival from an under-
lying cancer c0 is usually not of interest. Thus, given that survival from cancer
c0 is modelled adequently, the conclusions on survival from cancer of site c
are unlikely to be affected by the fixed effect of the underlying first cancer
c0. However, if multiple-cancer patients’ cancers are of the same site, a case
of special interest here (I-II), the ability to appropriately test hypotheses of
interest is essential.
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The method proposed by Sankila and Hakulinen [4, 10] could be considered
somewhat impractical and inflexible. The estimation of the life-table estimates
can be time-consuming and needs to be repeated with each change in the dis-
tribution of prognostic factors. Furthermore, if data on subsequent primary
cancer are sparse with respect to the distribution of prognostic factors, as they
are likely to be, life-table estimates can be unstable or non-consistent leading
to exclusion of some valuable subsequent primary cancers or to widening of
the categories of prognostic factors.
The use of individual patient data, on the other hand, may also have draw-
backs. When estimating survival from cancer as a first and subsequent tu-
mour, especially when they are not of the same site, the data may comprise
tens of thousands of individuals. If the hazards are also non-proportional and
the non-proportionality is handled by stratification, the number of parameters
easily multiplies to tens. Maximum likelihood estimation based on large data
with tens of parameters may be slow and even impossible due to limitations of
the software Splus5 under Linux and/or the computer used. Even in this case,
the data can be analysed, alike Sankila and Hakulinen, by fixing the hazard
of the underlying first cancer as discussed at the end of chapter 6.3.3 (III).
Note, however, that especially in this case, the estimate for λ2 can be highly
dependent on whether the model for the underlying hazard λf , f=0,1 fits, and
the standard errors of the parameters related to λ2 can be underestimated.
However, since the precision of the parameters related to λf is high, the size
of the underestimation is unlikely to have an effect in practice. For the semi-
parametric models (6)-(8), a flexible parametric form for the baseline hazard
τ could probably be used in reducing the number of parameters.
Since the method by Sankila and Hakulinen is semi-parametric, it can also
be included in the semi-parametric models when they are compared with the
parametric mixture model in the following section.
8.1.2 Semi-parametric models vs parametric mixture model
For the estimation of survival of multiple-cancer patients, the semi-parametric
models (6)-(8) (I,II,IV) and the method by Sankila and Hakulinen can gener-
ally be considered more useful than the parametric model (model (9) in III).
Some of the assumptions behind the parametric mixture model can be quite
restrictive and its use is thus limited. The hazard of a Weibull distribution
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(III) can be either decreasing (γ <1), increasing (γ >1) or constant (γ=1)
with respect to follow-up time. These alternatives cover the majority of the
cancers [29] but they do not include, for example, breast cancer for which
the lognormal distribution is more convenient [21, 30]. In addition, the as-
sumption of the independence of survival rates, given the values of prognostic
factors, can be questionable. On the other hand, when applicable, the para-
metric mixture model can have advantages over the semi-parametric ones. For
example, if the number of subsequent primary cancers is small during some
short follow-up time interval, the estimates for the piecewise constant baseline
hazards can be unstable (models (6)-(8)) whereas the estimates for αv and γv
are likely to be more stable given that the assumptions underlying model (9)
are appropriate.
8.1.3 Relative survival model vs cause-specific survival model
The estimation of survival from cancer c always requires more information than
when estimating overall survival: Either the cause of death or an expected
mortality hazard should be available for all patients. The analysis of relative
survival is often preferred over the cause-specific survival. An expected gen-
eral population mortality hazard may not, however, be an appropriate choice
for λe. As shown by Phillips et al. [18], cancer patients’ hazard of dying from
other causes can be different from that of the corresponding general population
group. For stomach cancer, for example, the ratio between the hazards (cancer
patients/general population) was reported to be 1.4 (95% CI 1.1-1.8). Thus if
one does not adjust cancer patients’ hazard of dying from other causes to be
higher (or lower) than that of the corresponding general population group, the
excess hazard may be overestimated (or underestimated). On the other hand,
due to continuous selection of the most robust individuals, the excess hazard
may underestimate the cause-specific hazard [31] and thus the cause-specific
survival may be lower than the respective relative survival.
In the Finnish data on patients with single and multiple breast cancers, es-
timates of model-based survival related to the first breast cancer were not
generally affected by the method of estimation; only among the oldest pa-
tients (at least 70 years at diagnosis) with a first localized breast cancer was
model-based relative survival higher than the respective survival based on the
cancer-specific survival models (7) and (8). This inequality between the ex-
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cess and cause-specific hazards has also been reported earlier for Norwegian
breast cancer patients aged at least 70 years [31]. A possible reason for this
difference could be that a death is too often coded as being due to cancer,
especially among the elderly.
8.1.4 Cancer-specific survival model 1 vs cancer-specific survival
model 2
The analysis of cause-specific survival of multiple-cancer patients raised a need
for new concepts: Survival from cancer should be distinguished between a
first and subsequent tumour. The need was especially evident when survival
of patients with one of two primary breast cancers was studied. Cancer- or
tumour-specific survival as well as c1 and c2 -specific survival were introduced
to refer directly to survival from specific cancers or tumours.
If data on cause of death are available, the analysis of cause-specific survival
of patients with multiple primary cancers at different sites should be possible
analogously to that of patients with single cancer. However, for a correspond-
ing analysis of patients with multiple primary cancers of the same site, the
cause of death should be defined to be either a first or subsequent cancer,
or non-cancer, i.e., the cancer-specific causes of death must be available (II).
These data were fortunately available at the Finnish Cancer Registry but are
often not available in other cancer registries. However, the analysis of Finnish
data on breast cancer showed that survival from the first and subsequent tu-
mour can be reliably estimated even if data on the cancer-specific causes of
death are not available. It can even be that subsequent breast cancer was too
often coded as a cause of death (model 1 in Figure 1).
8.2 Survival as a function of prognostic factors
Age at and calendar period of diagnosis and stage of cancer were considered
common prognostic factors and used in assessing survival from first and subse-
quent cancer in all the studies. In addition, time interval between the diagnoses
of the first and subsequent cancer and tumour rank were considered as poten-
tial prognostic factors for explaining survival from the subsequent cancer. The
former was thought to describe a possible association between the cancers and
the latter a ratio of the survival rates between a first and subsequent cancer of
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the same primary site. The effects of these prognostic factors on subsequent
cancer were clinically small (and statistically non-significant at the 5 % level)
in all the studies (I-IV). Nevertheless, it would be plausible to think that pa-
tients’ multiple cancers are associated with survival, especially if they are of
the same primary site. This association could not be assessed in these studies
or it does not have any relationship with time interval between the diagnoses.
On the other hand, the lack of the association could also be considered as a
consequence of the sufficient modeling of survival from first and subsequent
cancer.
The possible effect of screening with mammography on survival from the first
breast cancer was controlled for by excluding all first breast cancers which
may have been found due to the nationwide screening programme [32]. Since
individual data on the screened women were not available, the exclusion was
based on generalizations and assumptions: All breast cancers diagnosed among
the women invited for screening were assumed to be associated with screening
and the first breast cancers were diagnosed due to the screening programme if
they were diagnosed among the women scheduled to be screened in that year.
Furthermore, it was assumed that the screening programme was performed
similarly in each municipality. The assessment of screening might thus well be
incorrect at an individual level, but at the group level it lead to meaningful
results as interactions between age groups and calendar time were no longer
evident after making this exclusion. One could have also incorporated an addi-
tional covariate into the analysis for describing survival from screen-detected
first breast cancers. Both of these approaches were attempted and lead to
identical model-based survival from the first non-screen detected breast can-
cer.
In the parametric mixture model, prognostic factors were assumed to affect
both survival and proportion cured. In several other parametric mixture mod-
els, prognostic factors are assumed to affect survival through the scale param-
eter αv = exp(β1vzv) and the proportion non-cured through the logistic link
function, i.e., 1−Pv = exp(β2vzv)/(1+exp(β2vzv)) [15]. The parametric mix-
ture model applied was suitable for lung cancer with poor survival but could
be too inflexible for other sites of cancer.
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8.3 Non-proportionality of the hazards
The hazard λ due to cancer is often found to be non-proportional with respect
to stage of cancer and/or age of the patient. If the hazard λ1 of the first
cancer of site c is non-proportional with respect to stage of cancer and mean-
ingful comparisons are to be done, the hazard λ2 needs to be similarly non-
proportional. If the non-proportionality is accounted for by stratifying with
respect to a covariate zv1 with non-proportional effects, the number of param-
eters may increase extensively, especially in applications (I-II) and (IV). The
increase in the number of parameters with a simultaneous increase in the num-
ber of small strata may lead to problems in the estimation of λ2. The number
of small strata may affect not only the choice between the semi-parametric and
parametric models, discussed in 8.1.2, but also the formulation of the model
for λ2. If the parameters of λ2 are estimated freely, estimation may fail by
producing obscure estimates. For this reason, the parameters of λ2 were often
assumed to be dependent on those of a respective first cancer, that is, that the
effects of the common prognostic factors have to be considered to be at least
proportionally similar.
The non-proportionality of the hazards may not, however, last for the whole
follow-up time (III, [17]). In this case, time-dependent covariates are often
needed only for the first few years of the follow-up thus minimizing the prob-
lem with large numbers of parameters and small strata. A drawback of this
approach is that the number of time-dependent covariates included into a
model is likely to be data-driven.
According to Zahl and Tretli [31], the non-proportionality of the λ with re-
spect to stage of cancer and age group should be considered in the estimation
of long-term survival. For first cancers, the stratification is not a problem but
for subsequent cancers it can be, especially when cancer- and country-specific
data are used. Since stratification with respect to two or more factors with
non-proportional effects will probably lead to problems in the estimation of
the parameters related to subsequent cancer, the non-proportionality of the
λv with respect to two prognostic factors was not considered. For the same
reason, the classification of stage of cancer was relatively raw, non-localized
stage consisting of regional and distant metastases (II-IV). On the other hand,
the stratification by stage and age group might not always be necessary. The
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analysis of data on lung cancer with a parametric mixture model (III) showed
that if the excess hazard due to the first lung cancer was stratified by stage,
further stratification by age group did not have much effect on the results and
none on the conclusions.
8.4 Proportion cured from cancer as a first and subsequent
tumour
In the parametric mixture model (III), a patient is assumed, at the time of di-
agnosis, to belong to an unknown proportion cured from cancer or to a group
who will die from the cancer. In reality, the effectiveness of the cancer treat-
ment, for example, is likely to affect the group to which patient eventually
belongs.
The proportions cured from cancer were assessed in the parametric mixture
model but not in the other models. The proportions cured from cancer can,
however, be considered as limits of the long-term survival from cancer although
this interpretation is debated. The improved survival from cancer would lead
to an elevated proportion cured even if improved survival was due to an in-
crease in recurrence free survival time among the non-cured [33]. Different
alternatives for the relationship between the proportion cured and mean sur-
vival time have also been illustrated, for example, by Verdecchia et al. [34]. In
addition, the proportion cured from cancer is a limit of the long-term survival
from cancer only in a small class of proper distributions, and the class of im-
proper distributions is much wider [35].
8.5 Coding of multiple primary cancers
The conclusions from the results of these studies are dependent on the coding
of multiple primary cancers. Even if special attention has been paid to the
rules according to which a subsequent cancer is defined a new and indepen-
dent primary cancer, rather than a metastasis of a previous one, practices are
likely to vary. If the coding practice varies between countries, with calendar
time, time interval between the diagnoses of consecutive cancers and/or with
age of the patient, the comparability of the results may lack confidence. The
reliability of the coding of multiple primary cancers could be studied on a ’case
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by case’ -basis but that was not done since the coding as such was not of pri-
mary interest in this study. The coding practices of multiple primary cancers
were studied, however, by analysing the standardized incidence rates (SIRs)
of being diagnosed with a subsequent primary cancer with Poisson regression.
For comparisons of SIRs between the countries and with calendar periods of
diagnosis, the SIRs of a subsequent primary prostate cancer among the pa-
tients with a first colorectal cancer were analysed using the Danish, Finnish
and Norwegian data. For comparisons of SIRs between the calendar periods
of and age groups at diagnosis, and time intervals between the diagnoses, SIRs
of a subsequent primary breast cancer among the patients with a first primary
breast cancer were analysed using the Finnish data.
The SIRs of being diagnosed with a subsequent primary prostate cancer after
a first primary colorectal cancer are presented for each calendar time period
for Denmark, Finland and Norway, respectively, in Table 1. In Finland and
Norway, the SIRs were constant with the calendar time periods but they were
significantly different between the countries, about 1.19 in Finland and 1.55
in Norway. In Denmark, the SIRs varied significantly with calendar time
periods but were, however, at the same level as in Finland in calendar periods
1965-74 and 1985-96. Since the frequency of diagnosing prostate cancer is
not known to be affected by any extraneous factor, such as screening, during
the study period, there seemed to be a difference in the coding of multiple
primary cancers between Norway and the other countries. Consequently, if the
coding of multiple primary cancers is not comparable between the countries,
one should indeed be careful in comparing survival from subsequent cancer
between the countries.
Table 1: Observed number (OBS) and
standardized incidence ratio (SIR), with
95% confidence interval (95%CI), of be-
ing diagnosed with subsequent prostate
cancer by country and calendar period,
among patients with the first colorectal
cancer.
OBS SIR 95%CI
Denmark
1965-74 42 1.19 (0.86,1.61)
1975-84 179 1.67 (1.44,1.93)
1985-96 260 1.24 (1.09,1.40)
Finland
1965-74 8 1.17 (0.51,2.31)
1975-84 46 1.21 (0.89,1.62)
1985-97 182 1.19 (1.02,1.37)
Norway
1965-74 47 2.09 (1.54,2.78)
1975-84 145 1.52 (1.29,1.79)
1985-97 476 1.52 (1.38,1.66)
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The SIRs of being diagnosed with a subsequent breast cancer after the first
primary breast cancer are presented in Table 2. If the time interval between
the diagnoses of the first and subsequent breast cancer is short, less than two
years, the SIRs were significantly lower than in the other time intervals. This
result coincides with the practice of coding multiple primary breast cancers at
the Finnish Cancer Registry (II and personal discussion with Professor Lyly
Teppo, MD, Chief medical officer at the Finnish Cancer Registry 1972-2001).
For patients aged 50-59, the SIRs decreased significantly with calendar time.
With these exceptions, the SIRs support the conclusion that the coding of
multiple primary cancers has been consistent with calendar period and time
interval between the diagnoses of the first and subsequent breast cancer, and
increasing with age at diagnosis. The SIRs are known to be highest among the
youngest and decreasing with age [36]. Survival from a first and subsequent
breast cancer should thus be comparable (I,II) with respect to coding practice
of multiple primary cancers.
Table 2: Observed number (OBS) and standardized incidence ratio (SIR),
with 95% confidence interval (95%CI), of being diagnosed with subsequent
breast cancer among patients with a first breast cancer by age at diagnosis
of the first cancer (<50, 50-59, 60-69, 70+ years), time interval between the
diagnoses (<24, 24-59, 60-119,120+ months) and calendar period of diagnosis
of the first cancer (1968-86, 1987-96).
Time interval Calendar period
Age at diagnosis 1968-86 1987-96
OBS SIR 95%CI OBS SIR 95%CI
<24
<50 24 4.1 (2.6,6.1) 48 5.0 (3.7,6.6)
50-59 23 2.0 (1.3,3.1) 39 1.4 (1.0,2.0)
60-69 19 1.3 (0.8,2.0) 29 1.6 (1.1,2.3)
70+ 23 1.1 (0.7,1.7) 26 1.1 (0.7,1.6)
24-59
<50 38 8.3 (5.9,11.4) 77 8.9 (7.0,11.1)
50-59 47 4.1 (3.0,5.5) 69 2.3 (1.8,2.9)
60-69 53 3.6 (2.7,4.8) 67 2.9 (2.2,3.6)
70+ 45 2.1 (1.6,2.9) 72 2.3 (1.8,2.9)
60-119
<50 21 8.8 (5.5,13.5) 50 8.8 (6.5,11.6)
50-59 38 3.6 (2.5,4.9) 72 2.3 (1.8,2.9)
60-69 35 3.0 (2.1,4.1) 75 2.8 (2.2,3.6)
70+ 50 2.6 (1.9,3.4) 99 2.7 (2.2,3.2)
120+
<50 1 2.7 (0.0,15.2) 11 6.1 (3.0,10.9)
50-59 21 5.1 (3.2,7.9) 65 3.0 (2.3,3.8)
60-69 27 4.8 (3.1,6.9) 82 2.3 (1.9,2.9)
70+ 30 3.4 (2.7,4.8) 113 2.5 (2.0,2.9)
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8.6 Conclusions
Survival from subsequent cancer should be examined only if survival from the
underlying first cancer is controlled for. The overall survival of multiple-cancer
patients with respect to both cancers together will generally be worse than that
of single-cancer patients with either of these cancers as a first tumour. The
conclusions whether survival from cancer as a first and subsequent tumour are
really different (I-II) or equal (III,IV) should also be confirmed later with a
further increase in numbers of subsequent primary cancers. Such confirmation
can be possible, for example, if the international project EUROCARE [37] is
enlarged to consider survival of multiple-cancer patients.
Further development of the models for estimating survival from cancer as a first
and subsequent tumour would be worth considering. For the semi-parametric
models (I-II,IV), an alternative parametric formulation of the λv could be use-
ful. The measures for assessing the possible association with survival between
the first and subsequent cancer should also be improved.
With the current increase in the numbers of subsequent cancers, models for
estimating survival of multiple cancer patients are of growing need and im-
portance. With the concepts introduced and models developed in this thesis,
survival of patients with multiple cancers can be assessed and estimated with
respect to a first and subsequent tumour. The use of individual data on single-
and multiple-cancer patients enables analyses where survival from cancer as a
first or subsequent tumour can be estimated simultaneously. There are only
few assumptions underlying the first three models (6)-(8) and thus these mod-
els are generally applicable for any site of cancer. If needed, the presented
models can be modified for estimating observed survival and are also expand-
able for estimating survival of patients with more than two primary cancers.
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9 APPENDIX
THE FIRST AND SECOND DERIVATIVES OF THE LOG-LIKELIHOODS
Lcs1 AND Lcs2 OF MODELS (7) AND (8)
In the notations Rvk = exp(βvzvm), Rvk = exp(βvzvm), v=0,1,2, m=i,j; in-
dices a, b = 1, ...r stand for the elements of the parameter vectors βv, and
k, h=1,...,mv for the follow-up intervals.
Cancer-specific survival model 1 (model (7))
Cancer-specific cause of death known
The first derivatives of Lcs1(β0, β1, β2, τ0, τ1, τ2) are
∂Lcs1
∂β0a
=
N0∑
i=1
z0ia(−Λ0i + δ0i), ∂Lcs1
∂τ0k
=
N0∑
i=1
R0i(−t0ki + δ0iI0k(t0i)
λ0i
),
∂Lcs1
∂β2a
=
N0∑
i=1
c2iz2ia(−Λ2i + δ2i), ∂Lcs1
∂τ2k
=
N0∑
i=1
c2iR2i(−t2ki + c2iδ2iI2k(t2i)
λ2i
),
∂Lcs1
∂β1a
=
N1∑
j=1
z1ja(−Λ1j + δ1j), and ∂Lcs1
∂τ1k
=
N1∑
j=1
R1j(−t1kj + δ1jI1k(t1j)
λ1j
).
The second derivatives of Lcs1 are
∂2Lcs1
∂β0a∂β0b
=
N0∑
i=1
−z0iaz0ibΛ0i, ∂
2Lcs1
∂β0a∂τ0k
=
N0∑
i=1
−z0iaR0it0ki,
∂2Lcs1
∂τ0k∂τ0h
=
N0∑
i=1
−δ0iI0k(t0i)I0h(t0i)R
2
0i
λ20i
,
∂2Lcs1
∂β0a∂β1b
=
∂2Lcs1
∂β0a∂β2b
=
∂2Lcs1
∂β0a∂τ1k
=
∂2Lcs1
∂β0a∂τ2k
=
∂2Lcs1
∂τ0k∂τ1h
=
∂2Lcs1
∂τ0k∂τ2h
= 0,
∂2Lcs1
∂β2a∂β2b
=
N0∑
i=1
−c2iz2iaz2ibΛ2i, ∂
2Lcs1
∂β2a∂τ2k
=
N0∑
i=1
−c2iz2iaR2it2ki,
∂2Lcs1
∂τ2k∂τ2h
=
N0∑
i=1
−c2iδ2iI2k(t2i)I2h(t2i)R22i
λ22i
,
∂2Lcs1
∂β2a∂β1b
=
∂2Lcs1
∂β2a∂τ1k
=
∂2Lcs1
∂τ2k∂β1b
=
∂2Lcs1
∂τ2k∂τ1h
= 0,
∂2Lcs1
∂β1a∂β1b
=
N1∑
j=1
−z1jaz1jbΛ1j , ∂
2Lcs1
∂β1a∂τ1k
=
N1∑
j=1
−z1jaR1jt1jk, and
∂2Lcs1
∂τ1k∂τ1h
=
N1∑
j=1
−δ1jI1k(t1j)I1h(t1j)R
2
1j
λ21j
.
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Cancer-specific survival model 2 (model (8))
Cancer-specific cause of death not known
The first derivatives of Lcs2(β0, β1, β2, τ0, τ1, τ2) shown in (8) are
∂Lcs2
∂β0a
=
N0∑
i=1
z0ia(−Λ0i + δciλ0i
λ0i + c2iλ2i
),
∂Lcs2
∂τ0k
=
N0∑
i=1
R0i(−t0ki + δciI0k(t0i)
λ1i + c2iλ2i
),
∂Lcs2
∂β2a
=
N0∑
i=1
c2iz2ia(−Λ2i+ δciλ2i
λ0i + λ2i
),
∂Lcs2
∂τ2k
=
N0∑
i=1
c2iR2i(−t2ki+ δciI2k(t2i)
λ0i + λ2i
),
∂Lcs2
∂β1a
=
N1∑
j=1
z1ja(−Λ1j + δ1j), and ∂Lcs2∂τ1k =
∑N1
j=1R1j(−t1kj + δ1jI1k(t1j)λ1j ).
The second derivatives of Lcs2 are
∂2Lcs2
∂β0a∂β0b
=
N0∑
i=1
z0iaz0ib(−Λ0i + c2iδciλ0iλc2i(λ0i + λ2i)2 ),
∂2Lcs2
∂β0a∂τ0k
=
N0∑
i=1
z0iaR0i(−t0ki + c2iδciI0k(t0i)λ2i(λ0i + λ2i)2 ),
∂2Lcs2
∂τ0k∂τ0h
=
N0∑
i=1
−δciI0k(t0i)I0h(t0i)R
2
0i
(λ0i + c2iλ2i)2
,
∂2Lcs2
∂β0a∂β2b
=
N0∑
i=1
−c2iδciz0iaz2ibλ0iλc2i
(λ0i + λ2i)2
,
∂2Lcs2
∂β0a∂τ2k
=
N0∑
i=1
−c2iδciz0iaI2k(t2i)R2iλ0i
(λ0i + λ2i)2
,
∂2Lcs2
∂τ0k∂β2b
=
N0∑
i=1
−c2iδciz2ibI0k(t0i)R0iλ2i
(λ0i + λ2i)2
,
∂2Lcs2
∂τ0k∂τ2h
=
N0∑
i=1
−c2iδciI0k(t0i)I2h(t2i)R0iR2i
(λ0i + λ2i)2
,
∂2Lr
∂β0a∂β1b
=
∂2Lcs2
∂β0a∂τ1k
=
∂2Lcs2
∂τ0k∂τ1h
= 0,
∂2Lcs2
∂β2a∂β2b
=
N0∑
i=1
c2iz2iaz2ib(−Λ2i + δciλ0iλ2i(λ0i + λ2i)2 ),
∂2Lcs2
∂β2a∂τ2k
=
N0∑
i=1
c2iz2iaR2i(−t2ki + δciI2k(t2i)λ0i(λ0i + λ2i)2 ),
∂2Lcs2
∂τ2k∂τ2h
=
N0∑
i=1
−c2iδciI2k(t2i)I2h(t2i)R22i
(λ0i + λ2i)2
,
∂2Lcs2
∂β2a∂β1b
=
∂2Lcs2
∂β2a∂τ1k
=
∂2Lcs2
∂τ2k∂β1b
=
∂2Lcs2
∂τ2k∂τ1h
= 0,
∂2Lcs2
∂β1a∂β1b
=
N1∑
j=1
−z1jaz1jbΛ1j , ∂
2Lcs2
∂β1a∂τ1h
=
N1∑
j=1
−z1jaR1jt1hj , and
∂2Lcs2
∂τ1k∂τ1h
=
N1∑
j=1
−δ1jI1k(t1j)I1h(t1j)R
2
1j
λ21j
.
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